Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Regulation of Hematopoietic Stem Cells01:01

Regulation of Hematopoietic Stem Cells

4.2K
All blood and immune cells are produced from the multipotent hematopoietic stem cells (HSCs) by the process of hematopoiesis. However, they all have a limited life span. In addition, many are depleted in immune surveillance or combatting an injury or infection. This makes blood one of the most regenerative tissues. Hematopoiesis helps replenish these blood and immune cells, restoring the body's normal functioning. However, overproduction of blood and immune cells can make them cancerous or...
4.2K
Multipotency of Hematopoietic Stem Cells01:19

Multipotency of Hematopoietic Stem Cells

3.9K
The hematopoietic stem cells or HSCs are multipotent, meaning they can differentiate and give rise to all blood and immune cells. HSCs are maintained in the quiescent stage until an external stimulus initiates their differentiation. The multipotent HSCs exist as two heterogeneous populations, long-term repopulating cells (LTRC) and short-term repopulating cells (STRC). The two HSC populations have different surface markers or receptors and are classified based on quiescence and long-term...
3.9K
Hematopoiesis01:21

Hematopoiesis

9.2K
The process of blood cell formation is called hematopoiesis. Hematopoiesis starts early during development, on the seventh day of embryogenesis. This phase of hematopoiesis is called the primitive wave, wherein the extraembryonic yolk sac allows the production of erythroid cells and endothelial cells from a common precursor called hemangioblast. The erythroid cells provide oxygen to support the growth of the rapidly dividing embryo. Hemangioblasts later develop into hematopoietic stem cells or...
9.2K
Distinctive Features of Adult Stem Cells vs Cancer Stem Cells01:18

Distinctive Features of Adult Stem Cells vs Cancer Stem Cells

4.5K
A stem cell is an unspecialized cell that can divide without limit as needed and can, under specific conditions, differentiate into specialized cells.
Adult stem cells
Adult stem cells are tissue-specific; hence, they divide to develop the tissue from which they originate. One type of adult stem cell is the epithelial stem cell, which gives rise to the keratinocytes in the multiple layers of epithelial cells in the epidermis of the skin. Adult bone marrow has three distinct types of stem cells:...
4.5K
Stem Cell Therapy for Tissue Regeneration01:21

Stem Cell Therapy for Tissue Regeneration

4.7K
Stem cell therapy is a method used in regenerative medicine to repair and restore function to damaged tissues and organs. Stem cells have the potential to proliferate and differentiate into various tissue types, making them ideal candidates for tissue regeneration. For example, hematopoietic stem cell transplants are commonly used in blood cancer treatment to replenish damaged bone marrow and restore healthy blood cells.
Types of Stem Cells used in Stem Cell Therapy
The two main cell...
4.7K
Differentiation of Common Myeloid Progenitor Cells01:15

Differentiation of Common Myeloid Progenitor Cells

4.1K
Common myeloid progenitors (CMPs) are oligopotent cells that can differentiate into granulocytes and macrophages. Granulocytes and macrophages are essential for protecting the body against bacterial, viral, or fungal infections. They migrate from the bone marrow into the circulating blood to reach specific tissue sites where they differentiate and help in immune surveillance. However, they survive only for a few days and must be continuously made available to the organism to maintain a robust...
4.1K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

21st-Century Mangrove Expansion Along the Southeastern United States.

Global change biology·2026
Same author

Potential of CO<sub>2</sub> sequestration through accelerated weathering of limestone on ships.

Science advances·2025
Same author

A Close Look at Dissolved Silica Dynamics in Disko Bay, West Greenland.

Global biogeochemical cycles·2025
Same author

Extracellular vesicles released by ALL patients contain HNE-adducted proteins: Implications of collateral damage.

Free radical biology & medicine·2024
Same author

Post-sepsis chronic muscle weakness can be prevented by pharmacological protection of mitochondria.

Molecular medicine (Cambridge, Mass.)·2024
Same author

Correction to: Extraction of redox extracellular vesicles using exclusion‑based sample preparation.

Analytical and bioanalytical chemistry·2024

Related Experiment Video

Updated: Feb 19, 2026

Ex vivo Mimicry of Normal and Abnormal Human Hematopoiesis
11:50

Ex vivo Mimicry of Normal and Abnormal Human Hematopoiesis

Published on: April 10, 2012

16.0K

Hematopoietic Stem Cells: Normal Versus Malignant.

Dustin Carroll1, Daret K St Clair1

  • 1Department of Toxicology and Cancer Biology, College of Medicine, University of Kentucky , Lexington, Kentucky.

Antioxidants & Redox Signaling
|November 1, 2017
PubMed
Summary

Targeting the redox environment of hematopoietic stem cells (HSCs) and leukemic stem cells (LSCs) offers a novel cancer therapy approach. New treatments aim to protect normal HSCs while eliminating LSCs by modulating cellular redox states.

Keywords:
HSCLSChematopoiesisredox-active compoundstem cell function

More Related Videos

Use of Hematopoietic Stem Cell Transplantation to Assess the Origin of Myelodysplastic Syndrome
06:39

Use of Hematopoietic Stem Cell Transplantation to Assess the Origin of Myelodysplastic Syndrome

Published on: October 3, 2018

10.2K
Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up
09:01

Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up

Published on: March 26, 2018

14.8K

Related Experiment Videos

Last Updated: Feb 19, 2026

Ex vivo Mimicry of Normal and Abnormal Human Hematopoiesis
11:50

Ex vivo Mimicry of Normal and Abnormal Human Hematopoiesis

Published on: April 10, 2012

16.0K
Use of Hematopoietic Stem Cell Transplantation to Assess the Origin of Myelodysplastic Syndrome
06:39

Use of Hematopoietic Stem Cell Transplantation to Assess the Origin of Myelodysplastic Syndrome

Published on: October 3, 2018

10.2K
Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up
09:01

Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up

Published on: March 26, 2018

14.8K

Area of Science:

  • Hematology
  • Cancer Biology
  • Redox Biology

Background:

  • Long-term hematopoietic stem cells (LT-HSCs) self-renew and differentiate, maintaining blood cell production.
  • Deregulation of the redox environment in hematopoietic stem and progenitor cells (HSPCs) leads to exhaustion and mirrors leukemic stem cell (LSC) phenotypes.
  • The HSC/LSC redox environment is a druggable target in cancer research.

Purpose of the Study:

  • To explore redox-based therapeutic strategies for hematopoietic malignancies.
  • To investigate methods for protecting normal HSPC function while targeting LSCs.
  • To understand the role of redox balance in HSC/LSC transformation and therapy.

Main Methods:

  • Review of recent advances in redox-based therapies for hematopoietic malignancies.
  • Analysis of the critical balance required for therapeutic redox modulation.
  • Examination of how redox-based therapies impact metabolic and epigenetic factors.

Main Results:

  • New agents can protect normal HSPC function while inducing cytotoxicity in malignant populations.
  • Therapies can potentially reverse LSC transformation by restoring normal cell fate signaling.
  • A delicate balance is needed to exploit redox damage for therapeutic benefit without harming normal cells.

Conclusions:

  • Redox-based therapies represent a promising avenue for treating leukemias by selectively targeting LSCs.
  • Preserving normal HSPC redox balance is crucial for successful therapeutic outcomes.
  • Future research should focus on developing therapies that precisely modulate the HSC/LSC redox state.